Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benzo[D]Thiazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzo[D]Thiazole SCHEMBL28160889 | 0.98 | ALDH1A1 (0.73) | ALDH1A1HSD17B10MEN1KMT2AKDM4E | |
| Benzo[D]Thiazole SCHEMBL27956416 | 0.91 | ALDH1A1 (0.68) | ALDH1A1HSD17B10MEN1KMT2AKDM4E | |
| Benzo[D]Thiazole SCHEMBL28181260 | 0.88 | ALDH1A1 (0.63) | ALDH1A1HSD17B10MEN1KMT2AKDM4E | |
| Benzo[D]Thiazole SCHEMBL31388426 | 0.87 | — | — | |
| Benzo[D]Thiazole SCHEMBL10847268 | 0.87 | — | — | |
| Benzo[D]Thiazole SCHEMBL8430 | 0.87 | — | — | |
| Benzo[D]Thiazole SCHEMBL900814 | 0.87 | ALDH1A1 (1.00) | ALDH1A1HSD17B10KDM4ENPC1RAB9A | |
| Benzo[D]Thiazole SCHEMBL451685 | 0.87 | — | — | |
| Benzo[D]Thiazole SCHEMBL27537468 | 0.85 | ALDH1A1 (0.86) | ALDH1A1HSD17B10MEN1KMT2AKDM4E | |
| Benzo[D]Thiazole SCHEMBL5141989 | 0.85 | ALDH1A1 (0.95) | ALDH1A1HSD17B10KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501828-B1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | claimed |
| US-7314878-B2 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders | LABORATORIES SERONO SA (CH) | 2008-01-01 | — | — | US | claimed |
| CN-1310911-C | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2007-04-18 | — | — | CN | claimed |
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-11-24 | — | — | US | claimed |
| CN-1662528-A | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-31 | — | — | CN | claimed |
| EP-1501828-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | Applied Research Systems ARS Holding N.V. (AN) | 2005-02-02 | — | — | EP | claimed |
| WO-2003091249-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-11-06 | — | — | WO | claimed |
| CN-114814005-B | Liquid chromatographic analysis method for detecting ziprasidone in blood | 北京和合医学诊断技术股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-3458447-B1 | PIPERAZINYL METHANONE NAAA INHIBITORS | UNIV CALIFORNIA (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-109476616-B | Piperazinyl methanone NAAA inhibitors | 加利福尼亚大学董事会 | 2023-10-13 | — | — | CN | disclosed |
| CN-114814005-A | Liquid chromatography analysis method for detecting ziprasidone in blood | 北京和合医学诊断技术股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-10556892-B2 | Piperazinyl methanone NAAA inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190177313-A1 | PIPERZINYL METHANONE NAAA INHIBITORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-06-13 | — | — | US | disclosed |
| CN-1662528-A | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-31 | — | — | CN | disclosed |
| CN-1662528-A | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-31 | — | — | CN | disclosed |
| CN-1662528-A | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-31 | — | — | CN | disclosed |
| EP-1501828-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | Applied Research Systems ARS Holding N.V. (AN) | 2005-02-02 | — | — | EP | disclosed |
| EP-1501828-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | Applied Research Systems ARS Holding N.V. (AN) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091249-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091249-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177313-A1 | PIPERZINYL METHANONE NAAA INHIBITORS | NAAA, NAA15, NAA50 | ALDH1A1 1871/4885HSD17B10 629/4885MEN1 2432/4885 |
| US-10556892-B2 | Piperazinyl methanone NAAA inhibitors | NAAA, NAA50, NAA15 | ALDH1A1 2173/4885HSD17B10 327/4885MEN1 2272/4885 |
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | PRDX5, PIR, GRIK5 | ALDH1A1 474/4885HSD17B10 1950/4885MEN1 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.